Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gross, N.
Right arrow Articles by Skorodin, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gross, N.
Right arrow Articles by Skorodin, M.

Chest, Vol 96, 984-987, Copyright © 1989 by American College of Chest Physicians

ARTICLES

Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects

NJ Gross, E Co and MS Skorodin
Medical and Ambulatory Care Services, Hines VA Hospital, Maywood, IL.

The use of anticholinergic bronchodilators in COPD is based on the reversal of cholinergic bronchomotor tone. There is little information about the magnitude of cholinergic tone in patients with COPD as compared with normal subjects. As an index of the amount of cholinergic tone we measured the maximum increase in FEV1 following administration of an optimal dose of the anticholinergic agent atropine methonitrate. The study included nine normal nonsmoking subjects, ten normal smokers and 22 subjects with mild to moderately severe COPD. We found that normal nonsmokers had smallest increases in FEV1 following atropine methonitrate administration. Responses of subjects with airway disease were progressively greater. Greatest responses occurred in the group of subjects with prebronchodilator FEV1 values less than 55 percent of predicted. The most plausible explanation for this is that cholinergic tone in COPD is increased in proportion to the severity of airway disease. Other explanations are possible.


This article has been cited by other articles:


Home page
 Am. J. Respir. Cell Mol. Bio.Home page
Y. Chiba, M. Murata, H. Ushikubo, Y. Yoshikawa, A. Saitoh, H. Sakai, J. Kamei, and M. Misawa
Effect of Cigarette Smoke Exposure In Vivo on Bronchial Smooth Muscle Contractility In Vitro in Rats
Am. J. Respir. Cell Mol. Biol., December 1, 2005; 33(6): 574 - 581.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. J. Gross
Tiotropium Bromide
Chest, December 1, 2004; 126(6): 1946 - 1953.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D.-W. Perng, H.-Y. Huang, H.-M. Chen, Y.-C. Lee, and R.-P. Perng
Characteristics of Airway Inflammation and Bronchodilator Reversibility in COPD: A Potential Guide to Treatment
Chest, August 1, 2004; 126(2): 375 - 381.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. P. Tashkin and C. B. Cooper
The Role of Long-Acting Bronchodilators in the Management of Stable COPD
Chest, January 1, 2004; 125(1): 249 - 259.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
N J Gross
Responses to steroids and bronchodilators in COPD in the ISOLDE trial: the fat lady sings on
Thorax, August 1, 2003; 58(8): 647 - 648.
[Full Text] [PDF]

Home page
 ThoraxHome page
P M A Calverley, P S Burge, S Spencer, J A Anderson, and P W Jones
Bronchodilator reversibility testing in chronic obstructive pulmonary disease
Thorax, August 1, 2003; 58(8): 659 - 664.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. J. Gross
Outcome Measurements in COPD: Are We Schizophrenic?
Chest, May 1, 2003; 123(5): 1325 - 1327.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American College of Chest Physicians.